JP2009539802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539802A5 JP2009539802A5 JP2009513691A JP2009513691A JP2009539802A5 JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5 JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- mass
- pharmaceutical composition
- mpa
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims 3
- ULSWUGAAPQZIFJ-OWOJBTEDSA-N (E)-4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecoxy)-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)OCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ULSWUGAAPQZIFJ-OWOJBTEDSA-N 0.000 claims 3
- DCCSDBARQIPTGU-HSZRJFAPSA-N Fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 3
- 229960001021 Lactose Monohydrate Drugs 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 3
- 229960002675 Xylitol Drugs 0.000 claims 3
- 229960002978 fesoterodine Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- 239000000811 xylitol Substances 0.000 claims 3
- 235000010447 xylitol Nutrition 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 claims 1
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 206010036018 Pollakiuria Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
Claims (5)
- （ａ）０．３〜５．０質量％のフマル酸水素フェソテロジン、
（ｂ）５〜２５質量％のキシリトール、
（ｃ）２０〜４０質量％の、４５〜８０質量％のラクトース一水和物および５５〜２０質量％の微晶質セルロースを含む混合物、
（ｄ）２０〜６５質量％のヒドロキシプロピルメチルセルロース、
（ｅ）１〜５質量％のグリセロールジベヘナートおよび
（ｆ）１〜５質量％のタルク
を含む医薬組成物。 - （ａ）４．０ｍｇのフマル酸水素フェソテロジン、
（ｂ）３２〜４０ｍｇの平均粒径が０．００１〜０．３０ｍｍのキシリトール、
（ｃ）１１５〜１３０ｍｇの、４５〜８０質量％のラクトース一水和物および５５〜２０質量％の微晶質セルロースを含む混合物、
（ｄ）６５〜７５ｍｇの、水に溶解した場合（２質量％）の公称粘度が１００，０００ｍＰａ・ｓのヒドロキシプロピルメチルセルロース、
（ｅ）６５〜７５ｍｇの、水に溶解した場合（２質量％）の公称粘度が４，０００ｍＰａ・ｓのヒドロキシプロピルメチルセルロース、
（ｆ）８〜１２ｍｇのグリセロールジベヘナート、
（ｇ）７〜１０ｍｇのタルク、および
（ｈ）コーティング剤
を含む、請求項１に記載の医薬組成物。 - （ａ）８．０ｍｇのフマル酸水素フェソテロジン、
（ｂ）６５〜８０ｍｇの平均粒径が０．００１〜０．３０ｍｍのキシリトール、
（ｃ）７０〜８５ｍｇの、４５〜８０質量％のラクトース一水和物および５５〜２０質量％の微晶質セルロースを含む混合物、
（ｄ）１１０〜１３０ｍｇの、水に溶解した場合（２質量％）の公称粘度が１００，０００ｍＰａ・ｓのヒドロキシプロピルメチルセルロース、
（ｅ）２０〜３０ｍｇの、水に溶解した場合（２質量％）の公称粘度が４，０００ｍＰａ・ｓのヒドロキシプロピルメチルセルロースＨＰＭＣ、
（ｆ）８〜１２ｍｇのグリセロールジベヘナート、
（ｇ）７〜１０ｍｇのタルク、および
（ｈ）コーティング剤
を含む、請求項１に記載の医薬組成物。 - 過活動膀胱を治療するための、請求項１から３までのいずれか１項に記載の医薬組成物。
- 過活動膀胱が尿失禁、急迫性尿失禁、尿意切迫および／または尿意頻数の増加からなる群から選択される症状と関連付けられる、請求項４に記載の医薬組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06011941.9 | 2006-06-09 | ||
| EP06011941 | 2006-06-09 | ||
| EP06011943 | 2006-06-09 | ||
| EP06011943.5 | 2006-06-09 | ||
| EP06011942.7 | 2006-06-09 | ||
| EP06011942 | 2006-06-09 | ||
| PCT/EP2007/055582 WO2007141298A1 (en) | 2006-06-09 | 2007-06-06 | Stabilized pharmaceutical compositions comprising fesoterodine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011041842A Division JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539802A JP2009539802A (ja) | 2009-11-19 |
| JP2009539802A5 true JP2009539802A5 (ja) | 2011-05-06 |
| JP4743321B2 JP4743321B2 (ja) | 2011-08-10 |
Family
ID=38521333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513691A Active JP4743321B2 (ja) | 2006-06-09 | 2007-06-06 | フェソテロジンを含む安定した医薬組成物 |
| JP2011041842A Active JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011041842A Active JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP2029134B1 (ja) |
| JP (2) | JP4743321B2 (ja) |
| KR (1) | KR101316773B1 (ja) |
| CN (1) | CN101466371B (ja) |
| AP (1) | AP2416A (ja) |
| AR (1) | AR061289A1 (ja) |
| AT (1) | ATE517619T1 (ja) |
| AU (1) | AU2007255408B2 (ja) |
| BR (1) | BRPI0712865B1 (ja) |
| CA (1) | CA2652712C (ja) |
| CR (1) | CR10494A (ja) |
| CU (1) | CU23850B1 (ja) |
| CY (1) | CY1111934T1 (ja) |
| DK (1) | DK2029134T3 (ja) |
| EA (1) | EA015909B9 (ja) |
| EC (1) | ECSP089010A (ja) |
| ES (1) | ES2370943T3 (ja) |
| GT (1) | GT200800276A (ja) |
| HK (1) | HK1128626A1 (ja) |
| HR (1) | HRP20110776T1 (ja) |
| IL (2) | IL195732A (ja) |
| MA (1) | MA30504B1 (ja) |
| MX (1) | MX2008015736A (ja) |
| MY (1) | MY146574A (ja) |
| NI (1) | NI200800318A (ja) |
| NL (1) | NL2000690C2 (ja) |
| NO (1) | NO341980B1 (ja) |
| NZ (1) | NZ572616A (ja) |
| PE (2) | PE20080331A1 (ja) |
| PL (1) | PL2029134T3 (ja) |
| PT (1) | PT2029134E (ja) |
| RS (1) | RS51973B (ja) |
| SI (1) | SI2029134T1 (ja) |
| TN (1) | TNSN08505A1 (ja) |
| TW (2) | TWI397409B (ja) |
| UY (1) | UY30394A1 (ja) |
| WO (1) | WO2007141298A1 (ja) |
| ZA (1) | ZA200806411B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2294047A2 (en) * | 2008-04-04 | 2011-03-16 | Actavis Group PTC EHF | Novel mandelate salt of fesoterodine |
| IT1392082B1 (it) | 2008-12-10 | 2012-02-09 | Chemi Spa | Nuove forme solide della fesoterodina fumarato |
| CA2761602C (en) | 2009-05-11 | 2015-07-07 | Ratiopharm Gmbh | Desfesoterodine in the form of a tartaric acid salt |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| WO2011117884A1 (en) * | 2010-03-22 | 2011-09-29 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| TWI520732B (zh) | 2011-01-18 | 2016-02-11 | 輝瑞有限公司 | 固體分子分散液 |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| US20140199401A1 (en) * | 2011-07-04 | 2014-07-17 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of fesoterodine |
| WO2013046194A2 (en) * | 2012-05-18 | 2013-04-04 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| ES2674811T3 (es) * | 2012-07-02 | 2018-07-04 | Hetero Research Foundation | Composiciones estables de fesoterodina |
| DK2914255T3 (da) | 2012-11-02 | 2021-10-25 | Murray & Poole Entpr Ltd | Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin |
| AU2014255434B2 (en) | 2013-04-16 | 2018-11-08 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| CN105687154A (zh) * | 2014-11-27 | 2016-06-22 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| WO2019011393A1 (en) | 2017-07-12 | 2019-01-17 | Rontis Hellas S.A. | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF |
| TR201721437A2 (tr) * | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
| WO2019132832A1 (en) * | 2017-12-25 | 2019-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet compositions of fesoterodine fumarate |
| KR102018495B1 (ko) * | 2018-03-13 | 2019-09-05 | 충북대학교 산학협력단 | 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법 |
| EP3784217A1 (en) | 2018-04-26 | 2021-03-03 | Rontis Hellas S.A. | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof |
| CN110151720B (zh) * | 2019-05-09 | 2019-12-17 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| WO2023145486A1 (ja) * | 2022-01-28 | 2023-08-03 | 沢井製薬株式会社 | フェソテロジンフマル酸塩含有製剤の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999044604A1 (en) * | 1998-03-03 | 1999-09-10 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE29923134U1 (de) | 1999-11-16 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
| DE10224107A1 (de) * | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| DE10315878B4 (de) | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
-
2007
- 2007-06-06 CN CN2007800212925A patent/CN101466371B/zh not_active Expired - Fee Related
- 2007-06-06 CA CA2652712A patent/CA2652712C/en active Active
- 2007-06-06 EP EP07729956A patent/EP2029134B1/en active Active
- 2007-06-06 PT PT07729956T patent/PT2029134E/pt unknown
- 2007-06-06 NZ NZ572616A patent/NZ572616A/en not_active IP Right Cessation
- 2007-06-06 AT AT07729956T patent/ATE517619T1/de active
- 2007-06-06 JP JP2009513691A patent/JP4743321B2/ja active Active
- 2007-06-06 KR KR1020087027920A patent/KR101316773B1/ko active IP Right Grant
- 2007-06-06 AP AP2008004673A patent/AP2416A/xx active
- 2007-06-06 WO PCT/EP2007/055582 patent/WO2007141298A1/en active Application Filing
- 2007-06-06 EA EA200802444A patent/EA015909B9/ru active Protection Beyond IP Right Term
- 2007-06-06 TW TW096120242A patent/TWI397409B/zh not_active IP Right Cessation
- 2007-06-06 RS RS20110469A patent/RS51973B/en unknown
- 2007-06-06 MX MX2008015736A patent/MX2008015736A/es active IP Right Grant
- 2007-06-06 UY UY30394A patent/UY30394A1/es active IP Right Grant
- 2007-06-06 SI SI200730758T patent/SI2029134T1/sl unknown
- 2007-06-06 DK DK07729956.8T patent/DK2029134T3/da active
- 2007-06-06 PE PE2007000695A patent/PE20080331A1/es active IP Right Grant
- 2007-06-06 PE PE2011001996A patent/PE20120476A1/es not_active Application Discontinuation
- 2007-06-06 ES ES07729956T patent/ES2370943T3/es active Active
- 2007-06-06 AU AU2007255408A patent/AU2007255408B2/en not_active Ceased
- 2007-06-06 TW TW102118368A patent/TWI520735B/zh not_active IP Right Cessation
- 2007-06-06 BR BRPI0712865-7A patent/BRPI0712865B1/pt not_active IP Right Cessation
- 2007-06-06 PL PL07729956T patent/PL2029134T3/pl unknown
- 2007-06-06 MY MYPI20084409A patent/MY146574A/en unknown
- 2007-06-08 AR ARP070102485A patent/AR061289A1/es not_active Application Discontinuation
- 2007-06-08 NL NL2000690A patent/NL2000690C2/nl active Search and Examination
-
2008
- 2008-07-21 ZA ZA200806411A patent/ZA200806411B/xx unknown
- 2008-12-01 NI NI200800318A patent/NI200800318A/es unknown
- 2008-12-04 GT GT200800276A patent/GT200800276A/es unknown
- 2008-12-04 IL IL195732A patent/IL195732A/en not_active IP Right Cessation
- 2008-12-05 TN TNP2008000505A patent/TNSN08505A1/fr unknown
- 2008-12-08 MA MA31460A patent/MA30504B1/fr unknown
- 2008-12-08 CU CU2008000235A patent/CU23850B1/es active IP Right Grant
- 2008-12-11 CR CR10494A patent/CR10494A/es unknown
- 2008-12-24 EC EC2008009010A patent/ECSP089010A/es unknown
-
2009
- 2009-01-09 NO NO20090141A patent/NO341980B1/no unknown
- 2009-07-27 HK HK09106893.6A patent/HK1128626A1/xx not_active IP Right Cessation
-
2011
- 2011-02-28 JP JP2011041842A patent/JP4781489B2/ja active Active
- 2011-10-17 CY CY20111100983T patent/CY1111934T1/el unknown
- 2011-10-25 HR HR20110776T patent/HRP20110776T1/hr unknown
-
2012
- 2012-07-05 IL IL220800A patent/IL220800A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539802A5 (ja) | ||
| HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
| JP2014167026A5 (ja) | ||
| HRP20110776T1 (hr) | Stabilizirani farmaceutski sastavi koji sadrže fesoterodin | |
| JP2016006108A5 (ja) | ||
| RU2008148547A (ru) | Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением | |
| JP2009545560A5 (ja) | ||
| HRP20160454T1 (hr) | Kombinacija spoja morfinana i antidepresiva za liječenje pseudobulbarnog afekta | |
| JP2008534592A5 (ja) | ||
| JP2016525572A5 (ja) | ||
| JP2010209104A5 (ja) | ||
| JP2017537954A5 (ja) | ||
| JP2011510024A5 (ja) | ||
| JP2010523492A5 (ja) | ||
| JP2012518656A5 (ja) | ||
| JP2013535477A5 (ja) | ||
| JP2018138602A (ja) | 排尿頻度を減少させるための延長放出製剤およびその使用の方法 | |
| Maroni et al. | Polymeric coatings for a multiple-unit pulsatile delivery system: Preliminary study on free and applied films | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2014511374A5 (ja) | ||
| AR065539A1 (es) | Composiciones farmaceuticas que comprenden nanoparticulas que comprenden polimeros entericos y caseina | |
| JP2009536926A5 (ja) | ||
| JP2009521526A5 (ja) | ||
| RU2007103195A (ru) | Пероральная композиция тедисамила с замедленным высвобождением, обладающая свойством задержки в желудке | |
| JP2013514979A5 (ja) |